Progress in the Treatment of Metastatic Melanoma

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this podcast, a panel of experts discusses a range of topics relating to metastatic melanoma, including new treatment approaches, clinical trial updates, and managing side effects and pain. The participants on the panel were: Paul Chapman, MD, of the Memorial Sloan-Kettering Cancer Center; Gregory Daniels, MD, PhD, of the University of California San Diego; Mario Lacouture, MD, of the Memorial Sloan-Kettering Cancer Center; and Carolyn Messner, DSW, MSW, of CancerCare.
 
To listen to the podcast, click here.
Related Articles
Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.
Priced at approximately $178,000 for 2 courses of treatment, Blincyto will be one of the most expensive cancer medications on the market.
The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.
Merck’s anti–PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.
Latest Issues
$auto_registration$